IL-12 is a key promoter of cellular immune responses that has been shown to be therapeutically active against many murine tumors when used alone, or as a vaccine adjuvant. Use of rmIL-12 during vaccination with irradiated, genetically engineered SCK murine mammary tumor lines was shown recently to enhance vaccine efficacy but only after periods of immune suppression that severely compromised host tumor protection. Suppression may be a general effect of IL-12 and may be linked to transiently impaired splenic T cell mitogenesis responses. These observations suggest that non-immunological mechanisms activated by rmIL-12 promote tumor regression during the period of immune suppression. IFNg, which is secreted in response to IL-12, is required for these other mechanisms. IFNg clearly activates important host anti-tumor effects such as angiogenesis inhibition, but its effects on tumor cells are also important as shown by the refractoriness to rmIL-12 therapy of SCK cells rendered IFNg-un-responsive by expression of a dominant negative IFNgR. Studies in this application will examine mechanisms of tumor rejection activated by rmIL-12 and attempt to put them in an overall therapeutic perspective. Hypotheses to be tested are that (a) rmIL-12 enhances anti-tumor immunity but has immune suppressive effects the extent and cause of which need to be determined; (b) other tumoristatic or tumoricidal mechanisms activated by rmIL-12 through IFNg, such as angiogenesis inhibition, account for tumor regression during the period of immune suppression; and (c) specific genes or effectors activated by IFNg in tumor cells determine their susceptibility to rmIL-12 antitumor mechanisms. Specifically, Aim 1 will characterize conditions of rmIL-12 use that suppress and later enhance tumor vaccination and will define the enhancing and suppressive effects of reIL-12 on new and mature responses to tumor and allogeneic immunization.
Aim 2 will examine the role of IFNg and TNFa as mediators of suppression, and Aim 3 will examine the contribution of angiogenesis inhibition and other anti-tumor mechanisms during the rmIL-12 treatment of growing tumors to explain how regression is induced despite its immune suppressive effects.
Aim 4 will examine the susceptibility of tumor cells made unresponsive to IFNg by a dominant negative IFNgR to specific rmIL-12 anti-tumor mechanisms and will examine the role of candidate IFNg modulated genes in determining tumor cell susceptibility to rmIL-12.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA077851-03
Application #
6173653
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Yovandich, Jason L
Project Start
1998-07-01
Project End
2003-04-30
Budget Start
2000-05-01
Budget End
2001-04-30
Support Year
3
Fiscal Year
2000
Total Cost
$247,410
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Lassoued, Wiem; Murphy, Danielle; Tsai, Jeff et al. (2011) Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. Cancer Biol Ther 10:1326-33
Tsai, Jeff H; Lee, William M F (2009) Tie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy. Mol Cancer Res 7:300-10
Chen, Shao-Hua; Murphy, Danielle A; Lassoued, Wiem et al. (2008) Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol Ther 7:1994-2003
Murphy, Danielle A; Makonnen, Sosina; Lassoued, Wiem et al. (2006) Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 169:1875-85
Tsai, Jeff H; Makonnen, Sosina; Feldman, Michael et al. (2005) Ionizing radiation inhibits tumor neovascularization by inducing ineffective angiogenesis. Cancer Biol Ther 4:1395-1400
Gee, Michael S; Lee, William M F (2003) The role of tumor oxygenation in vascular and clinical response to angiogenesis inhibition. Adv Exp Med Biol 510:1-5
Gee, Michael S; Makonnen, Sosina; al-Kofahi, Khalid et al. (2003) Selective cytokine inhibitory drugs with enhanced antiangiogenic activity control tumor growth through vascular inhibition. Cancer Res 63:8073-8
Gee, Michael S; Procopio, William N; Makonnen, Sosina et al. (2003) Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 162:183-93
Lee, James C; Kim, David C; Gee, Michael S et al. (2002) Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomas. Cancer Res 62:747-55
Gee, M S; Saunders, H M; Lee, J C et al. (2001) Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res 61:2974-82